STEVENSON, Wash., Dec. 15, 2010 (GLOBE NEWSWIRE) -- www.globenewswire.com/newsroom/ctr%3Fd=202457%26l=1%26a=Total%2520Nutraceutical%2520Solutions%252C%2520Inc.%26u=http%253A%252F%252Fcts.businesswire.com%252Fct%252FCT%253Fid%253Dsmartlink%2526url%253Dhttp%25253A%25252F%25252Fwww.totalnutraceutical.com%25252F%2526esheet%253D6406055%2526lan%253Den-US%2526anchor%253DTotal%252BNutraceutical%252BSolutions%25252C%252BInc.%2526index%253D1%2526md5%253D9007c2facc810f88d9bbe1dba1cb81b8">Total Nutraceutical Solutions, Inc. (TNS) (OTCBB:TNUS), announced today that TNS will formulate and launch CardioSANO™, a breakthrough mushroom-based dietary supplement to nutritionally support heart health. The potential nutritional support of CardioSANO™, which contains natural ergothioneine, is based on a recently published scientific study by Dr. Keith R. Martin entitled: "The Bioactive Agent Ergothioneine, a Key Component of Dietary Mushrooms Inhibits Monocyte Binding to Endothelial Cells Characteristic of Early Cardiovascular Disease. J. of Medicinal Food, 13 (6) 2010, 1340-1346." Keith R. Martin, Ph.D, MTox, is Assistant Professor, College of Nursing and Health Innovation, Arizona State University, Mesa, Arizona.
Recent scientific research suggests that dietary bioactive agents with antioxidant activity can play an important protective role against pro-oxidative, pro-inflammatory diseases, such as cardiovascular diseases (CVD). The annual CVD death rate in the United States exceeds 1 million people. Ergothioneine (ERGO) is a potent natural antioxidant that must be consumed from dietary sources, such as mushrooms, as humans cannot synthesize this key bio-nutrient. In this published study, Dr. Martin demonstrated that ERGO confers anti-atherogenic bioactivity. He also raises the possibility that there is an ERGO transporter in human aortic endothelial cells which assists humans and animals to accumulate needed amounts of ERGO. TNS holds a license to the ERGO Transporter. The ERGO Transporter, specific gene symbol SLC22A4, is a protein that is within the cell membrane of red and white blood cells and whose role is to specifically deliver the potent antioxidant ERGO to these cells.
TNS, a global leader in the research and development of bioactive nutrients from mushrooms had, prior to Dr. Martin's findings, already positioned the company to develop breakthrough dietary supplements in the growing heart-healthy arena. The heart-healthy food and beverage market had $3.2 billion in global sales in 2009; www.nutraceuticalsworld.com/contents/view/29386. TNS has accumulated proprietary data and has licensed key technology and patents which form the basis for the development and launch of new heart healthy products. These license agreements include but are not limited to:
- Total Nutraceutical Solutions Acquires Ergothioneine Transporter License from the University of Cologne, Germany; Ergothioneine is a Natural Organic Potent Antioxidant. Date: March 15, 2010.
- Total Nutraceutical Solutions Licenses Pulsed UV Light Patent from the Penn State Research Foundation; Rapid Generation of Vitamin D2 from Mushrooms Using Pulsed UV Light. Date: June 9, 2010
"The antioxidant research done to date by TNS, the antioxidant patent licenses acquired and the companies potentially strong market position in the heart-healthy arena are strongly validated by Dr. Martin's scientific findings." stated Marvin S. Hausman MD, CEO, TNS. "Our company intends, as soon as possible, to introduce CardioSANO™ into the ever-expanding preventative heart-healthy market. TNS proprietary ERGO and vitamin D2 technology will form the basis for the nutritional value of this new product."
About Total Nutraceutical Solutions, Inc.:
TNS, a global biotechnology leader in whole food mushroom research and development, focuses on discovering, focuses on discovering, formulating and marketing products composed primarily of organic natural whole mushroom foods, containing bioactive nutrients, such as L-Ergothioneine and Vitamin D, with potential health benefits. Our scientific strategy is to specialize in the development of production and analytic technologies for food and nutritional supplements mainly composed of mushrooms and their mycelial biomasses. Novel clinical models and biomarkers are used to show nutritional and clinical efficacy of our products. In addition to our novel preventative healthcare formulations and nutritional approaches for a wide variety of human conditions and illnesses, we are also involved in the development, acquisition and ownership of breakthrough nutritional tools and products in the fields of animal husbandry and livestock feeds.
The Total Nutraceutical Solutions, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8060
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Total Nutraceutical Solutions (TNS), Inc., with the Securities and Exchange Commission. Further information on risks faced by TNS are detailed in the Form 10-K for the year ended December 31, 2009, and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. TNS does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.